Physicians' Academy for Cardiovascular Education
Slides: ASCVD risk reduction for patients with high Lp(a) in 2020: Is there a role for PCSK9 inhibition?

Slides: ASCVD risk reduction for patients with high Lp(a) in 2020: Is there a role for PCSK9 inhibition?

Slides (presentation) - Sep. 23, 2020 - Vera Bittner, MD - Birmingham, AL, USA - CME symposium held during virtual ESC Congress 2020

Slides as educational service to PACE members and meeting participants

This lecture was part of an accredited symposium "Lp(a), a new lipid frontier in CV risk management & target for therapy" held during the virtual ESC Congress 2020. The presentation was prepared and held by prof. Vera Bittner,

Professor of Medicine, Section Head, General Cardiology, Prevention and Imaging, Division of Cardiovascular Disease, University of Alabama at Birmingham, Birmingham, AL, USA.

Download presentation as pdf

View presentation slides

The content is aimed for medical professionals. To view this item member registration is needed. Register for free to get unlimited access to our educational resources.

Share this page with your colleagues and friends: